Altimmune Inc (ALT) Live Share Price, Invest From India

Altimmune Inc Stock Performance

as on March 24, 2026 at 4:10 am IST

Day's Low
Day's High
$3.32
Day's Price Range
$3.53
$3.44
3.49%
Downside
2.62%
Upside
52 Week's Low
52 Week's High
$2.90
52-Week Price Range
$7.73
$3.44
15.70%
Downside
124.71%
Upside

Altimmune Inc share price movements today

Previous Close: $3.34
Open: $3.40
Volume: 2.7M
Day's Low - High: $3.32 - $3.53
52 Week Low - High: $2.90 - $7.73

Altimmune Inc Historical Returns

1 Month Return: -26.11 %
3 Month Return: -16.5 %
1 Year Return: -42.51 %
3 Year Return: -20.29 %
5 Year Return: -76.74 %

Altimmune Inc Stock Fundamentals & Key Indicators

Check Altimmune Inc market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$434.6M

EPS (TTM)

-1.17

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

PEG Ratio

32.6168

EBITDA

-94.4M

Revenue (TTM)

41.0K

Profit Margin

0.00%

Return On Equity TTM

-50.57%

Altimmune Inc vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Altimmune Inc with its industry peers.

Company	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin %
Altimmune Inc	BUY	$434.6M	-76.74%	NA	0.00%
Alnylam Pharmaceuticals, Inc.	BUY	$41.4B	125.13%	133.41	8.45%
Vertex Pharmaceuticals Incorporated	BUY	$115.3B	112.56%	29.67	32.94%
Beone Medicines Ltd	NA	$31.6B	NA	111	5.37%
Regeneron Pharmaceuticals, Inc.	BUY	$77.5B	56.01%	17.67	31.41%

Stock Returns calculator for Altimmune Inc Stock including INR - Dollar returns

The Altimmune Inc stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Altimmune Inc investment value today

Current value as on today

₹69,128

Returns

₹30,872

(-30.87%)

Returns from Altimmune Inc Stock

₹40,792 (-40.79%)

Dollar Returns*

₹9,919 (+9.92%)

Analyst Recommendation on Altimmune Inc Stock

Based on 12 analysts

BUY

75.00%

Buy

25.00%

Hold

0.00%

Sell

Based on 12 analysts, 75% of analysts recommend a 'BUY' rating for Altimmune Inc. Average target price of $18

Altimmune Inc Share Price Target

Get share price movements and forecasts by analysts on Altimmune Inc.

What analysts predicted

80.89%UPSIDE

Target Price

$18

Current Price

$3.44

Analyzed by

12 Analysts

Target

$18.00

Altimmune Inc target price $18, a slight upside of 80.89% compared to current price of $3.44. According to 12 analysts rating.

Altimmune Inc Stock’s Investor Sentiment and Interest

Search interest for Altimmune Inc Stock has decreased by -64% in the last 30 days, reflecting a downward trend in search activity.

Time period: February 21, 2026 to March 23, 2026

Change:-64% versus previous 30 day period

Altimmune Inc Quarterly Profit & Loss

All numbers in Millions USD

	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Total Revenue	0	0	0	0	0	0	0	0	0	0
Gross Profit	-18	0	0	0	0	0	0	0	-14	0
Operating Income	-22	-33	-26	-26	-24	-24	-21	-22	-20	-28
EBITDA	-22	-29	-24	-24	-22	-23	-20	-21	-18	-28
Interest Expense	0	0	0	0	0	0	0	0	0	0
Depreciation	0	1	0	0	0	0	0	0	0	0
Income Before Tax	-20	-31	-24	-24	-22	-23	-20	-22	-19	-27
Income Tax Expense	0	1	-	-	-	-	0	-	-	-
Net Income	-20	-31	-24	-24	-22	-23	-19	-22	-19	-27
Net Profit Margin	-5710.22%	-85516.22%	-487880.00%	-492800.00%	-456900.00%	-463600.00%	-391500.00%	-442920.00%	-380280.00%	-105223.08%

Altimmune Inc Annual Profit & Loss

All numbers in Millions USD

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Revenue	5	0	10	5	8	4	0	0	0	0
Gross Profit	-1	-18	-8	5	-25	4	0	0	0	0
Operating Income	-11	-52	-42	-21	-54	-96	-87	-95	-103	-94
EBITDA	-10	-51	-44	-20	-38	-96	-84	-87	-94	-94
Interest Expense	0	0	0	0	0	0	0	0	0	1
Depreciation	-	0	0	0	0	0	0	0	0	0
Income Before Tax	205	-52	-45	-20	-43	-97	-84	-88	-95	-88
Income Tax Expense	11	-5	-6	0	5	0	0	0	-	0
Net Income	193	-46	-39	-20	-49	-97	-84	-88	-95	-88
Net Profit Margin	3706.44%	-111860.32%	-379.16%	-353.71%	-599.20%	-2201.59%	124577.94%	-20762.21%	-475295.00%	-214860.98%

Altimmune Inc Quarterly Cash Flow

All numbers in Millions USD

	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025
Net Income	-31	-24	-24	-22	-23	-19	-22	-19	-27
Operating Cash Flow	-16	-16	-18	-27	-18	-16	-19	-11	-19
Investing Cash Flow	-7	-39	-3	1	13	-5	101	-149	-79
Financing Cash Flow	72	0	0	0	10	34	52	39	81
Change in Cash	48	-56	-21	-25	5	12	134	-121	-17

Altimmune Inc Annual Cash Flow

All numbers in Millions USD

	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Net Income	-46	-39	-20	-49	-97	-84	-88	-95	-88
Operating Cash Flow	-20	-9	-9	-34	-78	-62	-75	-79	-67
Investing Cash Flow	13	-1	-28	-72	87	-73	13	-28	-132
Financing Cash Flow	15	32	12	213	65	56	86	10	206
Change in Cash	9	22	-25	106	74	-79	24	-98	6

Global Institutional Holdings in Altimmune Inc

Funds	Holdings
Geode Capital Management, LLC	1.76%
Point72 Asset Management, L.P.	0.37%
FMR Inc	0.43%
Vanguard Group Inc	7.3%
Caption Management, LLC	1.11%

See all

Insights on Altimmune Inc

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 5.0K → 26.0K (in $), with an average increase of 80.8% per quarter
NO EFFECT
Against Peers
In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 11.3% return, outperforming this stock by 53.8%
NO EFFECT
Against Peers
In the last 3 years, Altimmune Inc has experienced a drawdown of -20.3%, however Alnylam Pharmaceuticals, Inc. resisted the overall trend and outperformed by 11.7%
NEGATIVE IMPACT
Price Dip
In the last 1 month, ALT stock has moved down by -26.1%
NEGATIVE IMPACT
Profit Down
Netprofit is down for the last 2 quarters, -19.01M → -27.35M (in $), with an average decrease of 43.9% per quarter

About Altimmune Inc

altimmune, inc. is a clinical stage biotechnology company developing next-generation immunotherapeutics and vaccines to address significant public health and biodefense needs. by leveraging specific attributes of its two independent and complementary platform technologies, altimmune can rapidly design product candidates against a wide range of disease targets, including respiratory diseases, chronic infections, and cancer. our densigen™ t-cell platform technology is uniquely suited to direct the immune response against traditionally difficult disease targets, including chronic infections and cancer, by directing an individual’s immune system against multiple target antigens instead of just one. altimmune’s respirvec™ platform utilizes convenient needle-free intranasal delivery to achieve broad immunity against disease pathogens more rapidly than conventional vaccines. vaxin’s product candidates are easily manufactured, highly stable, and provide a safe, effective alternative to current

Organisation	Altimmune Inc
Headquarters	910 Clopper Road, Gaithersburg, MD, United States, 20878
Industry	Commercial Services
CEO	Mr. Jerome Benedict Durso
E-voting on shares	Click here to vote

Key Management of Altimmune Inc

Name	Title
Mr. Jerome Benedict Durso	Chairman, CEO & President
Dr. Christophe Arbet-Engels M.B.A., M.D., Ph.D.	Chief Medical Officer
Mr. Raymond M. Jordt M.B.A.	Chief Business Officer
Ms. Robin E. Abrams J.D.	Chief Legal Officer & Corporate Secretary
Ms. Linda M. Richardson	Chief Commercial Officer
Dr. M. Scot Roberts Ph.D.	Chief Scientific Officer
Mr. Gregory L. Weaver CPA, M.B.A.	Chief Financial Officer
Mr. Andrew Shutterly M.S.	Principal Financial & Accounting Officer and Corporate Controller
Mr. Bertrand Georges Ph.D.	Chief Technology Officer
Mr. Tony Blandin B.S.	Vice President of Quality & Compliance Management

FAQs

What is Altimmune Inc share price today?

Altimmune Inc share price today is $3.44 as on March 23, 2026 at 10:40 pm IST. Altimmune Inc share today touched a day high of $3.53 and a low of $3.32.

What is the 52 week high and 52 week low for Altimmune Inc share?

Altimmune Inc share touched a 52 week high of $7.73 on June 25, 2025 and a 52 week low of $2.9 on June 26, 2025. Altimmune Inc stock price today i.e. March 23, 2026 at 10:40 pm IST is trending at $3.44,which is 55.50% down from its 52 week high and 18.62% up from its 52 week low.

What is Altimmune Inc's market capitalisation today?

Altimmune Inc market capitalisation is $0.00T as on March 23, 2026 at 10:40 pm IST.

How to invest in Altimmune Inc Stock (ALT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Altimmune Inc on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Altimmune Inc Shares that will get you 0.4360 shares as per Altimmune Inc share price of $3.44 per share as on March 23, 2026 at 10:40 pm IST.

What is the minimum amount required to buy Altimmune Inc Stock (ALT) from India?

Indian investors can start investing in Altimmune Inc (ALT) shares with as little as ₹94.058 or $1 (as of March 23, 2026 at 10:40 pm IST) using the INDmoney app.
For example: If you want to invest $10 or ₹940.58 in Altimmune Inc stock (as per the Rupee-Dollar exchange rate as on March 23, 2026 at 10:40 pm IST). Based on Altimmune Inc share’s latest price of $3.44 as on March 23, 2026 at 10:40 pm IST, you will get 2.9070 shares of Altimmune Inc. Learn more about fractional shares .

What are the returns that Altimmune Inc has given to Indian investors in the last 5 years?

Altimmune Inc stock has given -76.74% share price returns and 29.13% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?